Kazuhiro Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazuhiro Yamamoto has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Aiko Takami
Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University
6 shared publications - Ichiro Hisatome
Yonago Medical Center, National Hospital Organization, Yonago 683-0006, Tottori, Japan
5 shared publications - Masahiko Kato
Division of School of Health Science, Department of Pathobiological Science and Technology, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan
5 shared publications - Yoshiharu Kinugasa
Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan
5 shared publications - Haruaki Ninomiya
Department of Biological Regulation, Tottori University Faculty of Medicine
4 shared publications - Junichiro Miake
Department of Health Sciences, Faculty of Medicine, Kagawa University, Kagawa, Japan
4 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (11) , 2034-2043
Fasting serum annexin A2 is associated with peripheral insulin sensitivity and may enhance glucose uptake via Src‐dependent signaling
Background and Aim: Subcellular annexin A2 (ANXA2) is known to regulate membrane dynamics and GLUT4 trafficking in adipocytes; however, the role of serum ANXA2 in glucose metabolism remains unclear. We aimed to investigate the association between fasting serum ANXA2 and insulin sensitivity in humans and to examine the role of extracellular ANXA2 in glucose uptake in cultured skeletal myocytes. Methods: We conducted a clinical study in 15 non‐diabetic Japanese adults who underwent hyperinsulinemic–euglycemic glucose clamp studies to assess peripheral insulin sensitivity. Fasting serum ANXA2 levels were measured and correlated with metabolic parameters. Cultured C2C12 myotubes were treated with recombinant human ANXA2 and the effects of ANXA2 on glucose uptake and insulin signaling mediators were evaluated. Results: Fasting serum ANXA2 showed a significant positive correlation with mean glucose infusion rate (mean GIR; r = 0.76, P = 0.00095). In C2C12 myotubes, both ANXA2 and insulin significantly increased glucose uptake compared with controls. ANXA2 enhanced IRS‐1 and Akt phosphorylation independently of insulin, and this effect was suppressed by the Src‐kinase inhibitor PP2. Conclusions: In conclusion, these results indicated that fasting serum ANXA2 is associated with peripheral insulin sensitivity in humans, and that exogenous ANXA2 may enhance glucose uptake in association with IRS‐1/Akt signaling and Src‐dependent pathways. Together, these findings support further evaluation of serum ANXA2 as a potential indicator reflecting peripheral insulin sensitivity.
- 4 September 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (11) , 2034-2043
Open AccessFasting serum annexin A2 is associated with peripheral insulin sensitivity and may enhance glucose uptake via Src‐dependent signaling
Background and Aim: Subcellular annexin A2 (ANXA2) is known to regulate membrane dynamics and GLUT4 trafficking in adipocytes; however, the role of serum ANXA2 in glucose metabolism remains unclear. We aimed to investigate the association between fasting serum ANXA2 and insulin sensitivity in humans and to examine the role of extracellular ANXA2 in glucose uptake in cultured skeletal myocytes. Methods: We conducted a clinical study in 15 non‐diabetic Japanese adults who underwent hyperinsulinemic–euglycemic glucose clamp studies to assess peripheral insulin sensitivity. Fasting serum ANXA2 levels were measured and correlated with metabolic parameters. Cultured C2C12 myotubes were treated with recombinant human ANXA2 and the effects of ANXA2 on glucose uptake and insulin signaling mediators were evaluated. Results: Fasting serum ANXA2 showed a significant positive correlation with mean glucose infusion rate (mean GIR; r = 0.76, P = 0.00095). In C2C12 myotubes, both ANXA2 and insulin significantly increased glucose uptake compared with controls. ANXA2 enhanced IRS‐1 and Akt phosphorylation independently of insulin, and this effect was suppressed by the Src‐kinase inhibitor PP2. Conclusions: In conclusion, these results indicated that fasting serum ANXA2 is associated with peripheral insulin sensitivity in humans, and that exogenous ANXA2 may enhance glucose uptake in association with IRS‐1/Akt signaling and Src‐dependent pathways. Together, these findings support further evaluation of serum ANXA2 as a potential indicator reflecting peripheral insulin sensitivity.
- Open Access
- 18 June 2025
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 25 (11) , 2153-2161
Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age
The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin is approved in Japan for the treatment of heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) and HF with preserved left ventricular ejection fraction (HFpEF). We conducted a post-marketing surveillance study of empagliflozin for HF in Japan. This was a 1-year prospective, multicenter, observational study of patients with chronic HF who had not previously received empagliflozin. The primary endpoint was incidence of adverse drug reactions (ADRs). Prespecified effectiveness endpoints were all-cause death, cardiovascular (CV) death, and hospitalization for HF (HHF). 1,166 patients were included (61.0% male, mean age 74.9 years). At baseline, mean left ventricular ejection fraction was 49.0%, mean body mass index was 24.2 ± 4.6 kg/m2, and 34.2% had type 2 diabetes. ADRs occurred in 61 (5.2%) patients overall, 5.8% of those aged ≥ 75 years, 6.2% of those aged 65 to < 75 years, and 2.2% of those aged < 65 years. Incidences of all-cause death, CV death, and HHF were 3.0, 0.9, and 2.5 per 100 PY, respectively. In this 1-year post-marketing surveillance study, empagliflozin was generally well-tolerated in patients with HF in Japan. ClinicalTrials.gov identifier is NCT05262764.
- 18 June 2025
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 25 (11) , 2153-2161
Open AccessSafety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age
The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin is approved in Japan for the treatment of heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) and HF with preserved left ventricular ejection fraction (HFpEF). We conducted a post-marketing surveillance study of empagliflozin for HF in Japan. This was a 1-year prospective, multicenter, observational study of patients with chronic HF who had not previously received empagliflozin. The primary endpoint was incidence of adverse drug reactions (ADRs). Prespecified effectiveness endpoints were all-cause death, cardiovascular (CV) death, and hospitalization for HF (HHF). 1,166 patients were included (61.0% male, mean age 74.9 years). At baseline, mean left ventricular ejection fraction was 49.0%, mean body mass index was 24.2 ± 4.6 kg/m2, and 34.2% had type 2 diabetes. ADRs occurred in 61 (5.2%) patients overall, 5.8% of those aged ≥ 75 years, 6.2% of those aged 65 to < 75 years, and 2.2% of those aged < 65 years. Incidences of all-cause death, CV death, and HHF were 3.0, 0.9, and 2.5 per 100 PY, respectively. In this 1-year post-marketing surveillance study, empagliflozin was generally well-tolerated in patients with HF in Japan. ClinicalTrials.gov identifier is NCT05262764.
- Open Access
Clinical Phenotypes Associated with the Gut Microbiome in Older Japanese People with Care Needs in a Nursing Home
Background: Frailty increases the risk of needing nursing care and significantly affects the life and functional prognosis of older individuals. Early detection and tailored interventions are crucial for maintaining and enhancing their life functions. Recognizing distinct clinical phenotypes is essential for devising appropriate interventions. This study aimed to explore diverse frailty phenotypes, focusing on poor nutrition in older Japanese individuals through observational research. Methods: Twenty-one nursing home residents underwent a comprehensive survey covering physical, blood, dietary, cardiac, cognitive, nutritional, nursing care, frailty, agitated behavior, and gut microbiome assessments (high-throughput 16S rRNA gene sequencing). Using clustering analysis with 239 survey items (excluding gut microbiome), participants were classified into subgroups based on clinical phenotypes, and group characteristics were compared through analysis. Results: Individuals with moderate or severe frailty and suspected dementia formed subgroups with distinct clinical phenotypes based on nutritional, defecation, and nursing care statuses. The gut microbiome significantly varied among these groups (p = 0.007), indicating its correlation with changes in clinical phenotype. Nutritional status differences suggested poor nutrition as a differentiating factor in the core clinical phenotype. Conclusions: This study proposes that the gut microbiome differs based on the clinical phenotype of Japanese older individuals with frailty, and targeted interventions addressing the gut microbiome may contribute to preventing frailty in this population.
Open AccessClinical Phenotypes Associated with the Gut Microbiome in Older Japanese People with Care Needs in a Nursing Home
Background: Frailty increases the risk of needing nursing care and significantly affects the life and functional prognosis of older individuals. Early detection and tailored interventions are crucial for maintaining and enhancing their life functions. Recognizing distinct clinical phenotypes is essential for devising appropriate interventions. This study aimed to explore diverse frailty phenotypes, focusing on poor nutrition in older Japanese individuals through observational research. Methods: Twenty-one nursing home residents underwent a comprehensive survey covering physical, blood, dietary, cardiac, cognitive, nutritional, nursing care, frailty, agitated behavior, and gut microbiome assessments (high-throughput 16S rRNA gene sequencing). Using clustering analysis with 239 survey items (excluding gut microbiome), participants were classified into subgroups based on clinical phenotypes, and group characteristics were compared through analysis. Results: Individuals with moderate or severe frailty and suspected dementia formed subgroups with distinct clinical phenotypes based on nutritional, defecation, and nursing care statuses. The gut microbiome significantly varied among these groups (p = 0.007), indicating its correlation with changes in clinical phenotype. Nutritional status differences suggested poor nutrition as a differentiating factor in the core clinical phenotype. Conclusions: This study proposes that the gut microbiome differs based on the clinical phenotype of Japanese older individuals with frailty, and targeted interventions addressing the gut microbiome may contribute to preventing frailty in this population.
- Open Access
- 23 August 2024
- Published by Elsevier in Clinical Nutrition Open Science
- Vol. 57, 241-252
Associations of serum branched-chain amino acid and marine omega-3 fatty acid levels with exercise intolerance in heart failure patients
- 23 August 2024
- Published by Elsevier in Clinical Nutrition Open Science
- Vol. 57, 241-252
Open AccessAssociations of serum branched-chain amino acid and marine omega-3 fatty acid levels with exercise intolerance in heart failure patients
- Open Access
- 6 August 2024
- Published by Elsevier in JACC: Asia
- Vol. 4 (8) , 634-635
The Impact of Cardiovascular Disease Is Different Even Within Southeast Asia
- 6 August 2024
- Published by Elsevier in JACC: Asia
- Vol. 4 (8) , 634-635
Open AccessThe Impact of Cardiovascular Disease Is Different Even Within Southeast Asia
- Open Access
- 29 September 2022
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 1
Right Heart Catheterisation with Dobutamine Stress Test for Evaluation of Right Ventricular Outflow Tract Obstruction 30 Years After Surgical Repair of Tetralogy of Fallot
Right ventricular outflow tract obstruction was suspected in a 32-year-old man with repaired tetralogy of Fallot and borderline indications for surgical. Right heart catheterisation with a dobutamine stress test was useful in assessing the dynamics and severity of right ventricular outflow tract obstruction and in determining the treatment strategy.
- 29 September 2022
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 1
Open AccessRight Heart Catheterisation with Dobutamine Stress Test for Evaluation of Right Ventricular Outflow Tract Obstruction 30 Years After Surgical Repair of Tetralogy of Fallot
Right ventricular outflow tract obstruction was suspected in a 32-year-old man with repaired tetralogy of Fallot and borderline indications for surgical. Right heart catheterisation with a dobutamine stress test was useful in assessing the dynamics and severity of right ventricular outflow tract obstruction and in determining the treatment strategy.
- Open Access
- 30 June 2022
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 1
Impact of BMI and Type of Ablation Procedure on Atrial Fibrillation Recurrence in Japanese Patients
Background: AF recurs more frequently after catheter ablation in individuals with a high BMI than it does in those with a normal BMI. However, the association between AF recurrence and BMI may be influenced by race. The authors investigated the relationship between BMI and AF recurrence after catheter ablation in Japanese patients. Methods: They enrolled 726 consecutive patients with paroxysmal or persistent AF (241 patients classified as overweight/obese [BMI ≥25 kg/m2] and 485 classified as non-overweight/obese [BMI <25 kg/m2]) who underwent cryoablation or radiofrequency ablation. The relationship between BMI and AF recurrence was assessed. Results: AF recurred in 183 patients (25.2%; 105 with paroxysmal AF and 78 with persistent AF). Median BMI differed significantly between patients with and without AF recurrence (23.9 kg/m2 [interquartile range: 21.6–26.9] versus 23.2 kg/m2 [interquartile range: 21.3–25.4]; p=0.011). Fisher’s exact test showed that the AF recurrence rate increased significantly with BMI in the radiofrequency ablation group (non-overweight/obese: 23.9% versus overweight/obese: 44.6%; p<0.001) but not in the cryoablation group (non-overweight/obese: 19.3% versus overweight/obese: 18.0%; p=0.883). Patients classified as overweight/obese had a significantly larger left atrial dimension, and left atrial dimension increased synergistically with persistent AF and increasing BMI. Conclusion: The AF recurrence rate in Japanese patients who underwent radiofrequency ablation, but not in those who underwent cryoablation, increased with BMI (especially BMI ≥25 kg/m2). Cryoablation may be superior to radiofrequency ablation in Japanese patients classified as overweight/obese.
- 30 June 2022
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 1
Open AccessImpact of BMI and Type of Ablation Procedure on Atrial Fibrillation Recurrence in Japanese Patients
Background: AF recurs more frequently after catheter ablation in individuals with a high BMI than it does in those with a normal BMI. However, the association between AF recurrence and BMI may be influenced by race. The authors investigated the relationship between BMI and AF recurrence after catheter ablation in Japanese patients. Methods: They enrolled 726 consecutive patients with paroxysmal or persistent AF (241 patients classified as overweight/obese [BMI ≥25 kg/m2] and 485 classified as non-overweight/obese [BMI <25 kg/m2]) who underwent cryoablation or radiofrequency ablation. The relationship between BMI and AF recurrence was assessed. Results: AF recurred in 183 patients (25.2%; 105 with paroxysmal AF and 78 with persistent AF). Median BMI differed significantly between patients with and without AF recurrence (23.9 kg/m2 [interquartile range: 21.6–26.9] versus 23.2 kg/m2 [interquartile range: 21.3–25.4]; p=0.011). Fisher’s exact test showed that the AF recurrence rate increased significantly with BMI in the radiofrequency ablation group (non-overweight/obese: 23.9% versus overweight/obese: 44.6%; p<0.001) but not in the cryoablation group (non-overweight/obese: 19.3% versus overweight/obese: 18.0%; p=0.883). Patients classified as overweight/obese had a significantly larger left atrial dimension, and left atrial dimension increased synergistically with persistent AF and increasing BMI. Conclusion: The AF recurrence rate in Japanese patients who underwent radiofrequency ablation, but not in those who underwent cryoablation, increased with BMI (especially BMI ≥25 kg/m2). Cryoablation may be superior to radiofrequency ablation in Japanese patients classified as overweight/obese.
- Open Access
- 4 May 2022
- Published by Elsevier in Journal of Urban Economics
- Vol. 130, 103455
Do people accept different cultures?
- 4 May 2022
- Published by Elsevier in Journal of Urban Economics
- Vol. 130, 103455
Open AccessDo people accept different cultures?
- Open Access
- 10 April 2022
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 21 (11) , 1411-1422
Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
Empagliflozin, a glucose-lowering drug licensed for type 2 diabetes (T2D), demonstrated tolerability and effectiveness overall in a post-marketing surveillance (PMS) study in Japan. However, the im...
- 10 April 2022
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 21 (11) , 1411-1422
Open AccessSafety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
Empagliflozin, a glucose-lowering drug licensed for type 2 diabetes (T2D), demonstrated tolerability and effectiveness overall in a post-marketing surveillance (PMS) study in Japan. However, the im...
- Open Access
- 30 March 2022
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 21 (10) , 1315-1328
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Empagliflozin, a sodium-glucose co-transporter-2 inhibitor, was licensed for treating type 2 diabetes (T2D) in Japan and elsewhere in recent years. We conducted a post-marketing surveillance study ...
- 30 March 2022
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 21 (10) , 1315-1328
Open AccessSafety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Empagliflozin, a sodium-glucose co-transporter-2 inhibitor, was licensed for treating type 2 diabetes (T2D) in Japan and elsewhere in recent years. We conducted a post-marketing surveillance study ...